To date, the phenotype spectrum of de novo ATP1A1 pathogenic variants has included neurodevelopmental disorders (including developmental delay, autism spectrum disorders, and epilepsy), emotional disorders, sleep disorders, and HSP. This evidence concerns the gene ATP1A1 and epilepsy.